Pinealon at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology - the same team responsible for Epithalon, Cortexin, and related Russian peptide bioregulators. It was designed to penetrate the blood-brain barrier and specifically target pineal gland function, modulating the synthesis of melatonin and influencing circadian biology.
In animal models, Pinealon has demonstrated neuroprotective effects, improved memory consolidation, reduced oxidative damage in brain tissue, and extended lifespan in mice under conditions of accelerated aging. Its mechanism appears to involve direct interaction with DNA regulatory elements in neuronal cells, modulating gene expression programs related to cell survival and antioxidant defense.
Like other Russian bioregulators, Pinealon is administered in short cycles (typically 10 days) and effects are reported to persist for months afterward. Human clinical data is limited and largely confined to Russian-language literature, though it has been used clinically in Russian geriatric medicine for several decades. Western interest has grown alongside the broader longevity peptide research trend.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.